You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


New BRCA-targeting drug could treat advanced prostate cancer

The Phase II clinical trial for talazoparib, a new BRCA-targeting, precision drug, has demonstrated slowed tumour growth in some patients with advanced prostate cancer.